PMID: 11919247Mar 29, 2002Paper

Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Robert S DipaolaSiu-Long Yao

Abstract

To evaluate safety and pharmacokinetics (PK), and determine the recommended dose for efficacy studies, of L-377202, a novel peptide conjugate of doxorubicin (Dox) that releases the active metabolites leucine-doxorubicin (Leu-Dox) and Dox on cleavage by membrane-bound prostate-specific antigen (PSA). Nineteen patients with advanced hormone-refractory prostate cancer were treated intravenously with 71 cycles of L-377202 at escalating dose levels of 20 (n = 1), 40 (n = 3), 80 (n = 4), 160 (n = 3), 225 (n = 6), and 315 mg/m(2) (n = 2) once every 3 weeks. Toxicity, response, and PK of L-377202 were assessed. L-377202 was well tolerated. Dose-limiting grade 4 neutropenia was noted in two of two patients administered 315 mg/m(2) (both patients were able to resume therapy at 225 mg/m(2)). The recommended dose for efficacy studies was 225 mg/m(2), which induced grade 4 neutropenia in one of six patients. PK studies demonstrated that L-377202 was metabolized to Leu-Dox and Dox. PK were linear; after administration of single doses of 225 mg/m(2), the mean area under the concentration-time profiles of L-377202, Leu-Dox, and Dox were 6 micromol x L/h, 4 micromol x L/h, and 1 micromol x L/h, and peak concentrations were 14 micromol/L, 5 micr...Continue Reading

References

May 1, 1980·Annals of Internal Medicine·F M Torti, S K Carter
Jan 1, 1995·Journal of Clinical Laboratory Analysis·M LevesqueE P Diamandis
Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I F TannockK C Murphy
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P W KantoffN J Vogelzang
Mar 4, 2000·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·D Jain
Jul 21, 2000·CA: a Cancer Journal for Clinicians·A K StewartH J Eyre

❮ Previous
Next ❯

Citations

Nov 11, 2003·Urology·Hans Lilja
Jul 16, 2003·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Henk J BroxtermanKlaas Hoekman
Apr 23, 2011·Molecular Pharmaceutics·Wanyi TaiKun Cheng
Nov 2, 2004·Nature Reviews. Cancer·Carla A Borgoño, Eleftherios P Diamandis
Sep 14, 2007·Nature Reviews. Cancer·Carlos López-Otín, Lynn M Matrisian
Jul 3, 2003·Journal of the National Cancer Institute·Samuel R DenmeadeJohn T Isaacs
Jun 5, 2003·Current Opinion in Oncology·Jonathan Rosenberg, Eric J Small
Apr 30, 2011·International Journal of Peptides·Madhu BiyaniKoichi Nishigaki
Dec 24, 2005·Expert Opinion on Biological Therapy·Girja S Shukla, David N Krag
Apr 11, 2015·Expert Opinion on Investigational Drugs·Vittore CeredaMario Roselli
Oct 24, 2012·Trends in Pharmacological Sciences·Georgia Sotiropoulou, Georgios Pampalakis
Mar 5, 2016·Expert Opinion on Therapeutic Targets·Margaritis Avgeris, Andreas Scorilas
Jan 22, 2008·British Journal of Pharmacology·J M AtkinsonJ H Gill
Aug 19, 2015·Mass Spectrometry Reviews·Sara CrottiMarco Agostini
May 5, 2004·Seminars in Oncology·Vasily J Assikis, Jonathan W Simons
Dec 23, 2014·Medicinal Research Reviews·Herve Aloysius, Longqin Hu
Feb 28, 2014·Expert Opinion on Therapeutic Targets·Konstantinos MavridisAndreas Scorilas
Jun 7, 2005·Expert Opinion on Therapeutic Targets·Ekatherine Asatiani, Edward P Gelmann
Aug 18, 2018·Expert Opinion on Therapeutic Targets·Daniela LoessnerViktor Magdolen
Oct 30, 2019·Cancer Metastasis Reviews·Afshin MoradiJyotsna Batra
Aug 20, 2002·The Oncologist·Susan GoodinRobert S DiPaola
Nov 30, 2004·Cancer Investigation·William A Denny
Aug 9, 2019·Cancer Chemotherapy and Pharmacology·J DelahousseA Paci
Nov 11, 2020·Drug Development Research·Selvaraj KunjiappanPanneerselvam Theivendren
Oct 25, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chih-Hung ChuangTian-Lu Cheng

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.